Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma - PubMed (original) (raw)
. 2009 May 15;69(10):4217-24.
doi: 10.1158/0008-5472.CAN-08-4915. Epub 2009 Apr 21.
Susan L Slager, Zachary S Fredericksen, Alice H Wang, Michelle M Manske, Steven Ziesmer, Mark Liebow, William R Macon, Stacey R Dillon, Thomas E Witzig, James R Cerhan, Stephen M Ansell
Affiliations
- PMID: 19383901
- PMCID: PMC2743448
- DOI: 10.1158/0008-5472.CAN-08-4915
Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma
Anne J Novak et al. Cancer Res. 2009.
Abstract
Elevated B-cell-activating factor (BAFF; TNFSF13B) levels have been found in patients with B-cell malignancies and autoimmune diseases, suggesting that it may play a pathogenic role. We previously found that a single nucleotide polymorphism (SNP) in the TNFSF13B promoter resulted in increased transcription, suggesting that genetic variation in TNFSF13B may influence its expression. We therefore wanted to determine if genetic variation in TNFSF13B is associated with high BAFF levels and non-Hogkin lymphoma (NHL) risk. We genotyped 9 tagSNPs within TNFSF13B in a clinic-based study of 441 NHL cases and 475 matched controls and evaluated the association of individual SNPs with risk of NHL; 3 tagSNPs were significant (P < 0.05). When categorized into low-, moderate-, and high-risk groups based on risk alleles, we found the permutation-corrected odds ratio for the trend to be 1.43 (P = 0.0019) for risk of B-cell NHL, 1.69 (P = 0.0093) for diffuse large B-cell lymphoma, 1.43 (P = 0.029) for follicular lymphoma, and 1.06 (P = 0.21) for chronic lymphocytic leukemia/small lymphocytic lymphoma. The mean serum BAFF level in those who carried the low-risk alleles was 2 ng/mL compared with 4.3 ng/mL in those with the high-risk alleles (P = 0.02). Taken together, our data suggest that genetic variation in the TNFSF13B gene is significantly associated with NHL risk and elevated serum BAFF levels.
Figures
Figure 1. TNFSF13B gene structure and tagSNP mapping
A. Three SNPs, rs1224141, rs12583006, and rs12428930 in TNFSF13B are significantly associated with NHL risk and are located in the non-coding region of TNFSF13B flanking exon 3. B. Linkage disequilibrium (LD) chart showing strong LD among rs1224141, rs12583006, and rs12428930. Numbers represent |D’| values and darker shading represents higher r^2 values of correlation between SNPs.
Figure 2. Association of elevated serum BAFF levels with the high risk TNFSF13B gene alleles and NHL
Serum BAFF levels were tested by ELISA as described in Materials and Methods. A. Serum from untreated cases who had been genotyped and carried either the TNFSF13B low risk alleles (n=8) or high risk alleles (n=42) and untreated controls that carried either the TNFSF13B low risk alleles (n=18) or high risk alleles (n=32) B. Serum BAFF levels in controls (n=50) versus cases (n=50). C. Serum BAFF levels by histologic subtype (DLBCL n=11, FL n=21). D Serum BAFF levels in DLBCL patients (n=57). E. Serum BAFF levels in FL patients (n=32). *p<0.05
Figure 3. Expression of ΔBAFF is not associated with the high risk TNFSF13B gene alleles
A. Expression of BAFF, ΔBAFF, and BAFFφ mRNA was determined by RT-PCR. Two DNA specimens and a no DNA template control are shown. B. ΔBAFF mRNA levels in individuals (untreated cases and controls) who carry the high risk alleles (n=42) versus low risk alleles (n=18) were determined by PCR. Primers were designed to amplify full-length BAFF as well as ΔBAFF and data were quantified and normalized to full-length BAFF as described in Materials and Methods. Values represent the ratio of the densitometric value of ΔBAFF/BAFF.
Similar articles
- B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome.
Nezos A, Papageorgiou A, Fragoulis G, Ioakeimidis D, Koutsilieris M, Tzioufas AG, Moutsopoulos HM, Voulgarelis M, Mavragani CP. Nezos A, et al. J Autoimmun. 2014 Jun;51:89-98. doi: 10.1016/j.jaut.2013.04.005. Epub 2013 Jul 9. J Autoimmun. 2014. PMID: 23845207 - Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk.
Wang SS, Purdue MP, Cerhan JR, Zheng T, Menashe I, Armstrong BK, Lan Q, Hartge P, Kricker A, Zhang Y, Morton LM, Vajdic CM, Holford TR, Severson RK, Grulich A, Leaderer BP, Davis S, Cozen W, Yeager M, Chanock SJ, Chatterjee N, Rothman N. Wang SS, et al. PLoS One. 2009;4(4):e5360. doi: 10.1371/journal.pone.0005360. Epub 2009 Apr 24. PLoS One. 2009. PMID: 19390683 Free PMC article. - B-cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non-Hodgkin's Lymphoma.
Gragnani L, Lorini S, Marri S, Rattotti S, Madia F, Zibellini S, Monti M, Basile U, Di Stasio E, Libra M, Arcaini L, Zignego AL. Gragnani L, et al. Hematol Oncol. 2022 Oct;40(4):658-666. doi: 10.1002/hon.3008. Epub 2022 May 2. Hematol Oncol. 2022. PMID: 35460540 Free PMC article. - Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma.
Yang S, Li JY, Xu W. Yang S, et al. Crit Rev Oncol Hematol. 2014 Aug;91(2):113-22. doi: 10.1016/j.critrevonc.2014.02.004. Epub 2014 Feb 23. Crit Rev Oncol Hematol. 2014. PMID: 24629840 Review. - Integrating understanding of epidemiology and genomics in B-cell non-Hodgkin lymphoma as a pathway to novel management strategies.
Glass S, Phan A, Williams JN, Flowers CR, Koff JL. Glass S, et al. Discov Med. 2016 Mar;21(115):181-8. Discov Med. 2016. PMID: 27115168 Free PMC article. Review.
Cited by
- Genomic Regions Associated with Resistance to Gastrointestinal Nematode Parasites in Sheep-A Review.
Cunha SMF, Lam S, Mallard B, Karrow NA, Cánovas Á. Cunha SMF, et al. Genes (Basel). 2024 Jan 30;15(2):187. doi: 10.3390/genes15020187. Genes (Basel). 2024. PMID: 38397178 Free PMC article. Review. - Single nucleotide polymorphisms in cytokine genes and their association with primary Sjögren's syndrome in Saudi patients: A cross-sectional study.
Alqahtani B, Daghestani M, Omair MA, Alenzi F, Alhamad EH, Tashkandy Y, Othman N, Warsy A, Halwani R. Alqahtani B, et al. Saudi Med J. 2023 Dec;44(12):1232-1239. doi: 10.15537/smj.2023.44.12.20230490. Saudi Med J. 2023. PMID: 38016737 Free PMC article. - RBM25 binds to and regulates alternative splicing levels of Slc38a9, Csf1, and Coro6 to affect immune and inflammatory processes in H9c2 cells.
Tian X, Zhou G, Li H, Zhang X, Zhao L, Zhang K, Wang L, Liu M, Liu C, Yang P. Tian X, et al. PeerJ. 2023 Nov 7;11:e16312. doi: 10.7717/peerj.16312. eCollection 2023. PeerJ. 2023. PMID: 37953772 Free PMC article. - Multi-phasic gene profiling using candidate gene approach predict the capacity of specific antibody production and maintenance following COVID-19 vaccination in Japanese population.
Takemoto Y, Tanimine N, Yoshinaka H, Tanaka Y, Takafuta T, Sugiyama A, Tanaka J, Ohdan H. Takemoto Y, et al. Front Immunol. 2023 Jul 26;14:1217206. doi: 10.3389/fimmu.2023.1217206. eCollection 2023. Front Immunol. 2023. PMID: 37564647 Free PMC article. - The BAFF-APRIL System in Cancer.
Ullah MA, Mackay F. Ullah MA, et al. Cancers (Basel). 2023 Mar 16;15(6):1791. doi: 10.3390/cancers15061791. Cancers (Basel). 2023. PMID: 36980677 Free PMC article. Review.
References
- Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260–263. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA121569/CA/NCI NIH HHS/United States
- R01 CA092104/CA/NCI NIH HHS/United States
- CA92153/CA/NCI NIH HHS/United States
- R01 CA092153/CA/NCI NIH HHS/United States
- P50 CA097274/CA/NCI NIH HHS/United States
- R21 CA121569-02/CA/NCI NIH HHS/United States
- P50 CA097274-05/CA/NCI NIH HHS/United States
- CA097274/CA/NCI NIH HHS/United States
- R01 CA092153-06/CA/NCI NIH HHS/United States
- R21 CA121569/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources